JP2009544614A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544614A5 JP2009544614A5 JP2009520846A JP2009520846A JP2009544614A5 JP 2009544614 A5 JP2009544614 A5 JP 2009544614A5 JP 2009520846 A JP2009520846 A JP 2009520846A JP 2009520846 A JP2009520846 A JP 2009520846A JP 2009544614 A5 JP2009544614 A5 JP 2009544614A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- herv
- composition
- polypeptide
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 40
- 241000713887 Human endogenous retrovirus Species 0.000 claims description 36
- 230000002163 immunogen Effects 0.000 claims description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 17
- 229920001184 polypeptide Polymers 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 13
- 230000004044 response Effects 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 230000005867 T cell response Effects 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 210000004400 mucous membrane Anatomy 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83246506P | 2006-07-21 | 2006-07-21 | |
| PCT/US2007/016403 WO2008011120A2 (en) | 2006-07-21 | 2007-07-19 | Human endogenous retrovirus polypeptide compositions and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009544614A JP2009544614A (ja) | 2009-12-17 |
| JP2009544614A5 true JP2009544614A5 (https=) | 2010-09-02 |
Family
ID=38957380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009520846A Pending JP2009544614A (ja) | 2006-07-21 | 2007-07-19 | ヒト内在性レトロウイルスポリペプチド組成物およびその使用法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20080171061A1 (https=) |
| EP (1) | EP2046380A4 (https=) |
| JP (1) | JP2009544614A (https=) |
| KR (1) | KR20090060410A (https=) |
| CN (1) | CN101557823A (https=) |
| AU (1) | AU2007275693A1 (https=) |
| BR (1) | BRPI0714714A2 (https=) |
| CA (1) | CA2658393A1 (https=) |
| IL (1) | IL196516A0 (https=) |
| MX (1) | MX2009000659A (https=) |
| NO (1) | NO20090818L (https=) |
| RU (1) | RU2009106089A (https=) |
| SG (1) | SG173997A1 (https=) |
| WO (1) | WO2008011120A2 (https=) |
| ZA (1) | ZA200900379B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8398983B2 (en) | 2005-06-27 | 2013-03-19 | Glaxosmithkline Biologicals, S.A. | Immunogenic composition |
| US20090297530A1 (en) | 2006-05-22 | 2009-12-03 | Feng Wang-Johanning | Herv-k antigens, antibodies, and methods |
| EP2340851A4 (en) * | 2008-09-18 | 2012-09-26 | Univ Keio | DIAGNOSTIC METHOD AND THERAPEUTIC METHOD FOR CANCER |
| WO2010053772A2 (en) | 2008-10-29 | 2010-05-14 | The Regents Of The University Of California | Disease-associated antigens and methods of use thereof |
| EP2519539A4 (en) * | 2009-12-28 | 2013-11-13 | Ligocyte Pharmaceuticals Inc | METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES |
| US20120321637A1 (en) * | 2011-06-20 | 2012-12-20 | The Board Of Regents Of The University Of Texas System | Combination cancer therapy with herv inhibition |
| US11918557B2 (en) | 2012-01-26 | 2024-03-05 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
| WO2013112951A2 (en) | 2012-01-26 | 2013-08-01 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
| WO2014153114A1 (en) * | 2013-03-14 | 2014-09-25 | Fred Hutchinson Cancer Research Center | Compositions and methods to modify cells for therapeutic objectives |
| US10376487B2 (en) | 2013-11-12 | 2019-08-13 | Vanda Pharmaceuticals Inc. | Method of treatment |
| US11090285B2 (en) | 2013-11-12 | 2021-08-17 | Vanda Pharmaceuticals Inc | Treatment of circadian rhythm disorders |
| US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| WO2018006054A1 (en) * | 2016-06-30 | 2018-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Herv-e reactive t cell receptors and methods of use |
| CN109863165A (zh) * | 2016-08-23 | 2019-06-07 | 爱姆维恩公司 | 新型免疫刺激肽 |
| JP7348063B2 (ja) | 2017-01-05 | 2023-09-20 | フレッド ハッチンソン キャンサー センター | ワクチン効力を改善するためのシステム及び方法 |
| US12303561B2 (en) | 2017-04-03 | 2025-05-20 | Biontech Us Inc. | Protein antigens and uses thereof |
| AU2018322831B2 (en) * | 2017-09-01 | 2023-04-27 | Inprother Aps | A vaccine for use in the prophylaxis and/or treatment of a disease |
| US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
| CN111629715A (zh) | 2018-01-18 | 2020-09-04 | 弗莱德哈钦森癌症研究中心 | 通过调节细胞活化状态改变体内免疫细胞的炎症状态 |
| BR112020025764A2 (pt) | 2018-06-19 | 2021-05-11 | Biontech Us Inc. | neoantígenos e usos dos mesmos |
| IL281253B2 (en) * | 2018-09-06 | 2024-07-01 | Centre Leon Berard | Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine |
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| EP4185600A4 (en) | 2020-07-24 | 2024-12-04 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| US20240189247A1 (en) * | 2022-11-16 | 2024-06-13 | The General Hospital Corporation | Minimal Human-Derived Virus-Like Particles and Methods of Use Thereof for Delivery of Biomolecules |
| US20260035415A1 (en) * | 2024-08-01 | 2026-02-05 | Twilight Bioscience, Inc. | Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030092145A1 (en) * | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
| US20030162263A1 (en) * | 2001-09-06 | 2003-08-28 | Marc Dupuis | Peptides derived from the superantigen (SAg) ENV protein of HERV-K18 and their use in obtaining SAG-inhibitory antibodies and in vaccination against SAG |
| AT411262B (de) * | 2001-09-27 | 2003-11-25 | Wolff Klaus Dr | Humanes endogenes retrovirus |
| WO2003050258A2 (en) * | 2001-12-07 | 2003-06-19 | Chiron Corporation | Endogenous retrovirus polypeptides linked to oncogenic transformation |
| US20040096457A1 (en) * | 2001-12-11 | 2004-05-20 | Huber Brigitte T | Treatment and prevention of ebv infection and ebv-associated disorders |
| EP1338606A1 (en) * | 2002-02-22 | 2003-08-27 | Magnus Von Knebel Doeberitz | Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer |
| EP2516459A1 (en) * | 2009-12-22 | 2012-10-31 | Aarhus Universitet (University Of Aarhus) | Bivalent molecules for hiv entry inhibition |
| US20120321637A1 (en) * | 2011-06-20 | 2012-12-20 | The Board Of Regents Of The University Of Texas System | Combination cancer therapy with herv inhibition |
-
2007
- 2007-07-19 ZA ZA200900379A patent/ZA200900379B/xx unknown
- 2007-07-19 US US11/880,126 patent/US20080171061A1/en not_active Abandoned
- 2007-07-19 RU RU2009106089/15A patent/RU2009106089A/ru not_active Application Discontinuation
- 2007-07-19 WO PCT/US2007/016403 patent/WO2008011120A2/en not_active Ceased
- 2007-07-19 CA CA002658393A patent/CA2658393A1/en not_active Abandoned
- 2007-07-19 MX MX2009000659A patent/MX2009000659A/es not_active Application Discontinuation
- 2007-07-19 BR BRPI0714714-7A patent/BRPI0714714A2/pt not_active IP Right Cessation
- 2007-07-19 AU AU2007275693A patent/AU2007275693A1/en not_active Abandoned
- 2007-07-19 EP EP07836155.7A patent/EP2046380A4/en not_active Withdrawn
- 2007-07-19 SG SG2011052784A patent/SG173997A1/en unknown
- 2007-07-19 JP JP2009520846A patent/JP2009544614A/ja active Pending
- 2007-07-19 KR KR1020097003239A patent/KR20090060410A/ko not_active Withdrawn
- 2007-07-19 CN CNA2007800276077A patent/CN101557823A/zh active Pending
-
2009
- 2009-01-14 IL IL196516A patent/IL196516A0/en unknown
- 2009-02-20 NO NO20090818A patent/NO20090818L/no not_active Application Discontinuation
-
2013
- 2013-05-10 US US13/891,970 patent/US20130323279A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009544614A5 (https=) | ||
| RU2009106089A (ru) | Композиции, содержащие полипептид эндогенного ретровируса человека, и способы их применения | |
| TW202200199A (zh) | 冠狀病毒疫苗及使用方法 | |
| Ide et al. | Peptide‐loaded dendritic‐cell vaccination followed by treatment interruption for chronic HIV‐1 infection: a phase 1 trial | |
| EP3156068B1 (en) | Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof | |
| Fifis et al. | Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice | |
| EP2247306B1 (en) | Immunogenic control of tumours and tumour cells | |
| JP6780852B2 (ja) | Ｂ型肝炎ウイルス感染に対する治療ワクチン接種のための合成長鎖ペプチド（ｓｌｐ） | |
| TW200930400A (en) | Influenza antigen delivery vectors and constructs | |
| PT1035865E (pt) | Tat do hiv-1 ou respectivos derivados para vacinação profiláctica e terapêutica | |
| CN111533812B (zh) | 针对sars-cov-2病毒的dna疫苗及其用途 | |
| RU2011138160A (ru) | Пептиды foxmi и вакцины, содержащие их | |
| JP2025003964A (ja) | 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原 | |
| JP2011522777A5 (https=) | ||
| Memarnejadian et al. | Fusion of HBsAg and prime/boosting augment Th1 and CTL responses to HCV polytope DNA vaccine | |
| JP2013523084A5 (https=) | ||
| JP2012526519A5 (https=) | ||
| Chen et al. | Identification of SARS-COV spike protein-derived and HLA-A2-restricted human CTL epitopes by using a new muramyl dipeptide-derivative adjuvant | |
| JP2014506114A5 (https=) | ||
| JP2018508181A5 (https=) | ||
| JP2010029217A (ja) | Ｈｉｖ特異的ｃｔｌを誘導し得るペプチド及び該ペプチドを含む抗ａｉｄｓ予防・治療剤 | |
| RU2011140168A (ru) | Пептиды vangl1 и содержащие их вакцины | |
| Lei et al. | CD40L-adjuvanted DNA vaccine carrying EBV-LMP2 antigen enhances anti-tumor effect in NPC transplantation tumor animal | |
| Poh et al. | Characterization of cytotoxic T‐lymphocyte epitopes and immune responses to SARS coronavirus spike DNA vaccine expressing the RGD‐integrin‐binding motif | |
| US20120219583A1 (en) | Nucleic acid sequences encoding expandable hiv mosaic proteins |